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Box 1 Searching strategy designed for Embase database 
1. exp hydroxymethylglutaryl coenzyme A reductase inhibitor/ 
2. hydroxymethylglutaryl*.tw. 
3. HMG-CoA*.tw. 
4. (statin or statins).tw. 
5. cerivastatin.tw. 
6. fluvastatin.tw. 
7. lovastatin.tw. 
8. atorvastatin.tw. 
9. pravastatin.tw. 
10. simvastatin.tw. 
11 . lipitor.tw. 
12. baycol.tw. 
13. lescol.tw. 
14. mevacor.tw. 
15. altocor.tw. 
16. pravachol.tw. 
17. lipostat.tw. 
18. zocor.tw. 
19. mevinolin.tw. 
20. compactin.tw. 
21 . fluindostatin.tw. 
22. rosuvastatin.tw. 
23. dalvastatin.tw. 
24. cranoc.tw. 
25. canef.tw. 
26. locol.tw. 
27. lochol.tw. 
28. leucol.tw. 
29. lescol.tw. 
30. monacolin.tw. 
31. medostatin.tw. 
32. mevinacor.tw. 
33. livalo.tw. 
34. pitava.tw. 
35. pitavastatin.tw. 
36. pravasin.tw. 
37. mevalotin.tw. 
38. gerosim.tw. 
39. lipex.tw. 
40. zenas.tw. 
41 . crestor.tw 
42. meglutol.tw. 
43. or/1-42 
44. exp cardiovascular disease/ 
45. cardio*.tw. 
46. cardia*.tw. 
47. heart*.tw. 
48. coronary*.tw. 
49. angina*.tw. 
50. hyperlipidemia/ 
51. exp cholesterol/ 
52. exp lipid blood level/ 
53. hyperlipid*.tw. 
54. hypercholesterol*.tw. 
55. cholesterol*.tw. 
56. hypercholester?emia*.tw. 
57. hyperlip?emia*.tw. 
58. triglycerid*.tw. 
59. hypertriglycerid?emia*.tw. 
Continued 
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Box 1 Continued 
60. hyperlipoprotein?emia*.tw. 
61 . LDL.tw. 
62. HDL.tw. 
63. or/44-62 
64. 43 and 63 
65. limit 64 to yr="2012 -Current' 
66. (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab. 
67. retracted article/ 
68. 66 or67 
69. (animal$ not human$). sh, hw. 
70. (book or conference paper or editorial or letter or review).pt. not exp randomized controlled trial/ 
71. (random sampl& or random digit$ or random effect$ or random survey or random regression).ti,ab. not exp randomized controlled trial/ 
72. 69 or 70 or 71 
73. 68 not 72 
people aged 60years or more represented 12.5% of the 
global population in 2015 and this will increase to an 
estimated 16.7% in 2030.4 This will undoubtedly increase 
government expenditure on healthcare. On a popu-
lation basis, primary prevention is very important for 
CVD prevention as healthy people represent the largest 
proportion of the general population. Therefore, the 
greatest potential for reduction in major adverse cardio-
vascular events (MACE) resides in this population.5 
Statins (hydroxy-methyl-glutaryl-coenzyme A reduc-
tase inhibitors) have been shown to reduce MACE and 
mortality-in both middle-aged and older adults.6 7 The 
Box 2 Characteristics of included articles 
~ Method: type of study. 
~ Participants: sample size; country; age range (mean±SD); 
proportion of females; baseline low-density lipoprotein level; risk 
level of cardiovascular disease; any comorbidity such as diabetes or 
hypertension; loss to follow-up. 
~ Interventions: the name, dose and frequency of statins; comparison 
group; intervention in run-in phase; duration of follow-up and run-in 
phase. 
~ Outcomes: the primary outcome is statin-associated muscle 
symptoms (SAMS); The secondary outcomes are myopathy, 
rhabdomyolysis, adverse events (AEs), serious AEs, dropouts due to 
SAMS in run-in phase, total permanent discontinuations of statins 
and discontinuations due to AEs and especially muscular problems 
and a creatine kinase level ~5times upper limit of normal. 
~ Notes: whether trials stop prematurely; conflicts of interest. 
Box 3 Seven domains involved in Cochrane assessment 
tool for risk of bias 
~ Random sequence generation (selection bias) 
~ Allocation concealment (selection bias) 
~ Blinding of participants and personnel (performance bias) 
~ Blinding of outcome assessment (detection bias) 
~ Incomplete outcome data (attrition bias) 
~ Selective reporting (reporting bias) 
~ Other sources of bias (other bias) 
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beneficial effect of statins on survival is evident l-2years 
after commencing statin treatment.8 A meta-analysis of 
observational studies found that about half of patients 
initiated on statins discontinued their medication within 
a year. Taking statins for primary prevention was deter-
mined to be a main predictor ofnon-adherence.9 10 Only 
one in four people aged over 65years was adherent to 
statins after 2years of commencing statin for primary 
prevention.8 Additionally, statin users aged over 70years 
have lower adherence rates than middle-aged adults 
( 50-69 years). 10 While there are various reasons for statin 
discontinuation, two-thirds of the patients reported 
statin-related adverse effects as the reason.11 Older indi-
viduals are more vulnerable to adverse effects of drugs 
compared with younger individuals due to their phys-
ical deconditioning (decreased muscle mass and poorer 
renal and hepatic clearance), multiple morbidity and 
polypharmacy.12 13 Recognised statin-associated adverse 
effects include musculoskeletal dysfunction, hepatotox-
icity, new-onset type 2 diabetes and some other rare but 
significant adverse effects such as cancer, kidney disease 
and cataract.14---16 Of these, statin-associated muscle symp-
toms (SAMS), generally defined as all muscle-related 
complaints such as muscle pain or aching (myalgia), 
tenderness, stiffness, cramp and weakness, are the most 
commonly encountered adverse events (AEs) both in 
clinical studies and daily clinical practice.17 It is estimated 
that more than 1.5 million people per year experience 
SAMS.18 Of note, myopathy and rhabdomyolysis, which 
accompanied with high creatine kinase ( CK) level, are 
two severe statin-related musculoskeletal diseases that 
rarely happen but are potentially life threatening. 
Statins are recommended to be initiated during early 
middle age for people with clinical atherosclerotic 
cardiovascular disease (ASCVD) and high estimated 
10-year ASCVD risk due to the well-documented bene-
fits in middle-aged adults.2 19 20 Although the benefi-
cial effects of statins in the middle and younger adults 
are well documented, the older individuals have been 
under-represented in statin clinical trials, particularly 
those focusing on primary prevention and drug safety. 21 22 
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j Table 1 The scoring system provided by GRADE Working Group on assessing the quality of the evidence 
TyP.e of evidence 
Initial score based on +4 
type of evidence +2 
RCTs/SR of RCTs,+/-othertypes of evidence 
Observational evidence (eg, cohort, case-control} 
Quali 
Based on Blinding and allocation process 
Follow-up and withdrawals 
Sparse data 
Other methodological concerns (eg, incomplete reporting, subjective outcomes) 
Score Score 0,-1, -2,-3 represents 'no problems', problem with one element', 'problem with two elements', 
'problem with three elements', respectively. 
Consistency 
Based on Degree of consistency of effect between or within studies 
Score + 1 Evidence of dose response across or within studies (or inconsistency across studies is 
explained by a dose response); also one point added if adjustment for confounders would have 
increased the effect size 
0 All/most studies show similar results 
-1 Lack of agreement between studies (eg, statistical heterogeneity between RCTs, conflicting 
results) 
Directness 
Based on The generalisability of population and outcomes from each study to our population of interest 
Score Score 0,-1, -2 represents 'population and outcomes broadly generalisable', 'problem with one element', 
'problem with two or more elements', respectively. 
Effect size 
Based on The re orted OR/RR/HR for com arison 
Score 0 Not all effect sizes >2 or <0.5 and significant; or if OR/RR/HR not significant 
+1 Effect size >2o r<0.5for all studies/meta-analyses included in comparison and significant 
+2 Effect size >5or <0.2for all studies/meta-analyses included in comparison and significant 
GRADE, Grading of Recommendations Assessment, Development and Evaluation; RCTs, randomised controlled trials; SR, systematic review; 
OR, odds ratio; RR, relative risk; HR, hazard ratio. 
There is still no definitive indication of statin therapy in 
the low-risk elderly due to a lack of evidence from clin-
ical studies or meta-analyses ( cited in Class Ilb and Level 
of evidence in European Society of Cardiology guide-
lines) and making work more challenging in routine 
clinical practice.19 To our knowledge, one meta-anal-
ysis indicated that there is no excess risk of myopathy 
in older adults who received statins for both primary 
and secondary prevention, while no prior systematic 
review has ever primarily investigated the risk of SAMS 
among older people who received statins for only 
primary prevention.23 Clearly, studies are required, both 
randomised controlled trials (RCTs) (such as StaREE: 
Statins in Reducing Events in the Elderly, which is an 
ongoing blind, placebo-controlled clinical trial of statin 
therapy in primary prevention elderly: NCT02099123) 
and meta-analyses to provide evidence on drug safety 
of statin therapy prescribed in older adults for primary 
prevention of CVD and further to facilitate optimal 
prescribing and management approaches to minimise 
the side effects. 
4 
Objectives 
We will primarily determine the risk of SAMS among older 
people (~65years) who have received statins for primary 
prevention. In addition, we will determine the risk of 
myopathy, rhabdomyolysis, the AEs and serious adverse 
events (SAEs), the number of dropouts due to SAMS in 
run-in period, total permanent discontinuations (results 
from all cause) and permanent discontinuations related 
to AEs and specifically, muscular problems, patients with 
a CK level ~5 times upper limit of normal (ULN) among 
the same subpopulation group. 
METHODS 
This study has been designed and developed according 
to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses Protocols statement.24 The 
protocol was registered with the International Prospec-
tive Register of Systematic Reviews (registration no 
CRD420I 7058436). 
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Eligibility criteria 
Studies will be selected according to the criteria outlined 
below. 
Study design 
We will include double-blind, randomised, placebo 
controlled trials. We will exclude RCTs with an open 
comparator, non-randomised controlled trials and obser-
vational studies ( eg, cohort studies). 
Participants 
We will include studies with participants who do not have 
established CVD. In addition, eligible studies should 
have restricted inclusion to participants aged 65years or 
older or have provided a subanalysis for this group. Also 
eligible are studies in which the authors are willing to 
share patient-level data so that this age restriction can be 
imposed as part of this analysis. We will exclude studies 
that included patients with specialised pre-existing 
disease such as cancer, hypothyroidism, acute infection, 
chronic renal disease, HIV, post-transplantation or any 
other acute illness that might affect the study outcomes. 
Interventions 
We will include studies with a statin ( eg, atorvastatin, 
fluvastatin, lovastatin, pravastatin, rosuvastatin or simvas-
tatin) as the intervention and placebo as comparator. We 
will exclude studies using cerivastatin as a statin since it 
was withdrawn from the market due to a high risk of rhab-
domyolysis. 25 We will also exclude the studies in which the 
combination of any other lipid-lowering medications and 
statin was used as an intervention. 
Timing 
Studies should have a follow-up time of at least of 1 year to 
be eligible for inclusion. 
Outcomes 
Studies should report at least one of the following 
outcomes to be eligible: SAMS, myopathy, rhabdomy-
olysis, AEs, SAEs, dropouts due to SAMS in run-in period, 
total permanent discontinuations of statins and discon-
tinuations due to AEs or muscular problems, elevation in 
CK defined as a CK level ~5 times ULN. 
Language 
There will be no restrictions by language of publication. 
Search strategy 
This systematic review will be an update of a rele-
vant Cochrane systematic review in which the articles 
published prior to 2012 were identified.26 This Cochrane 
review included a larger population because it was aimed 
at statin therapy for primary prevention across all age 
groups. For the articles published before 1 January 2012, 
we will make a further assessment by selecting the eligible 
articles from the articles included in this Cochrane 
review. For the articles published from 1 January 2012 to 
13 February 2017, we will establish a new search using the 
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same search strategy listed in the Cochrane review apart 
from the publication date. The Cochrane Central Register 
of Controlled Trials, Medline OvidSP and Embase data-
bases will be performed to identify any relevant articles 
published. A combination of medical subject headings 
terms (such as 'Hydroxymethylglutaryl-CoA Reductase 
Inhibitors' , 'Hyperlipidemias', 'Cholesterol', 'Cardio-
vascular Diseases') and related free text terms (such 
as 'hydroxymethylglutaryl*', 'cardio*', 'hyperlipid*', 
'cholesterol*') will be used. Term 'random$ or placebo$ 
or single blind$ or double blind$ or triple blind$' will be 
used to filter the RCTs. Furthermore, we will hand search 
the relevant review articles to help retrieve all eligible 
trials. A complete Embase search strategy is included in 
box 1. The search strategy will be adapted to the other 
databases. 
Selection process 
Records from three databases will be exported to Endnote 
V.X8 (Bid 10063). After removing duplicate records, two 
review authors (ZZ and LA) will independently screen the 
title and abstract against the eligibility criteria. Discrep-
ancies will be resolved by consensus after discussion. A 
recommendation will be given by the third author (MN) 
if consensus cannot be reached. The full text for titles and 
abstracts that meet the inclusion criteria will be obtained. 
Two review authors (ZZ and LA) will independently 
screen the full text of identified records and record the 
reasons for excluding trials. 
Data extraction 
We will use a standardised data extraction sheet to extract 
data from each included study. Data extracted will include 
study characteristics, methodology, intervention details 
and all relevant outcomes (see box 2 for extracted data). 
We will contact study authors to obtain missing data. 
Outcomes and prioritisation 
1. The primary outcome is SAMS. Of note, we will 
only consider symptomatic muscular symptoms that 
matter to the participant, which included myalgia 
(muscle pain), muscle weakness, stiffness, tenderness 
and cramp.27 Asymptomatic, such as haematological 
index and pathological alteration will not be taken 
into account as they are less significant to participants 
who care more about symptomatic problems that 
compromise their life quality. 
2. Our secondary outcome will measure myopath1 (defined as SAMS with CK >10xULN)1 ; 
rhabdomyolysis ( defined as SAMS with CK >40x ULN 
when accompanied with renal impairmen t and/ 
or myoglobinuria) 17; AEs; SAEs (defined as adverse 
experiences that were considered serious including 
life threatening, causing death or a permanent 
disability or incapacity, resulting in or prolonging 
hospitalisation28); dropouts due to SAMS in run-
in period; Total permanent discontinuations to 
statins and permanent discontinuations to statins 
5 
Open Access @ 
due to adverse effects-related and specifically, 
muscular problem-related reasons in RCTs, compared 
with placebo group. Additionally, we will also examine 
the incidence of high CK level ~5xULN as this is a 
meaningful predictor of myotoxicity. 
Quality assessment (risk of bias of individual studies) 
Two independent review authors (ZZ and LA) will assess 
the risk of bias of all included studies separately. We will 
use the Cochrane Collaboration tool for assessinf the 
risk of bias, which include seven specific domains2 (see 
box 3 for the seven assessment criteria). Each domain will 
be assessed and categorised as 'Low risk', 'High risk' or 
'Unclear risk' of bias. Two figures will be generated using 
RevMan in our article. One is a 'Risk of bias graph' figure 
that will present the proportion of studies with each of the 
assessments for each entry in the tool. Another is a 'Risk 
of bias summary' figure that will show all assessments in a 
cross-tab for each study. 29 
Data synthesis and analysis 
For all primary and secondary outcomes in our study, as 
dichotomous data, relative risks (RRs) with 95% confi-
dence intervals (Cis) will be calculated for the pooled 
effects. Statistical analysis of outcomes will be based on 
'intention-to-treat' principle. The statistical heteroge-
neity between individual studies as measured by 12 test will 
be reported.30 I2 values of 30% to 60%, 50% to 90%, 75% 
to 100% may indicate moderate, substantial and consid-
erable heterogeneity, respectively.29 In view of the varia-
tion of the follow-up duration, the type and the dosage of 
statins and the assessment methods on AEs profile across 
the included RCTs, the random-effects model (DerSimo-
nian and Laird method) will be fitted in our study.31 32 
We will not perform a meta-analysis if the heterogeneity 
is substantial or there is a lack of data for any compar-
ison; a narrative, qualitative summary will be done. Where 
significant heterogeneity is present, meta-regression and 
subgroup analyses for the primary outcome will also 
be conducted to identify the sources of heterogeneity 
according to the following covariates: statin solubility 
(hydrophilic or lipophilic), dose (standard or intensive) 
and type of statins, study duration, gender and different 
comorbidities of subjects (such as diabetes and hyperten-
sion). In addition to this, a leave-one-out sensitivity anal-
ysis will be conducted by iteratively removing one study at 
a time to assess the impact of each study. STATA statistical 
software V.14.2 (Stata/SE for windows) will be used for all 
the analyses. 
Publication bias assessment 
Publication bias will be assessed using the funnel plot test 
if the number of articles is sufficient (> 10). Asymmetry 
identified in the funnel plot implies possible publication 
bias.29 In addition to this, contour-enhanced meta-anal-
ysis funnel plots will be conducted to distin~uish publica-
tion bias from other causes of asymmetry.3 The Egger's 
regression-intercept test will also be performed to identify 
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publication bias.34 The funnel plots and Egger's regres-
sion test will be generated by STATA. 
Confidence in cumulative evidence 
The scoring system (table 1) provided by the Grading of 
Recommendations Assessment, Development and Evalu-
ation (GRADE) Working Group will be used to assess the 
quality of the evidence. After summarising the score of 
each item in GRADE, the final score will be categorised 
to four levels: high (~4points), moderate (three points), 
low (two points), very low c::;;1 point).35 
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